SAN
FRANCISCO, Jan. 30, 2024 /PRNewswire/ --
Invitae (NYSE: NVTA), a leading medical genetics company,
today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq:
BBIO), a commercial-stage biopharmaceutical company focused on
genetic diseases and cancers, designed to advance genetics-based
drug discovery for rare diseases. The goal of the collaboration is
to generate new insights focused on genetic modifiers and the
discovery of novel therapeutic targets for rare diseases and other
unmet medical needs.
The agreement expands upon the longstanding partnership between
the two companies to combine the strengths of BridgeBio's deep
expertise in rare disease research and development of therapeutics,
and Invitae's rare disease enriched dataset and analytical
capabilities. Invitae has provided clinical testing for more than 4
million patients, generating an extensive dataset that is uniquely
positioned to deepen insights on patients with genetic-driven
disease.
"Invitae is on a mission to bring comprehensive genetic
information into mainstream medicine to improve healthcare for
billions of people. By leveraging de-identified genetic information
from patients, our researchers can gain a much deeper understanding
of the genetic basis of a disease," said W. Michael Korn, M.D., chief medical officer at
Invitae. "Through this partnership, we aim to support the
development of novel therapeutic targets and advance transformative
medicines for patients with rare disease."
Access to large genetic and clinical datasets are needed to
advance research and discover novel drug targets and are often hard
to find for researchers.
"We chose to partner with Invitae because of the unique scale
and depth of their dataset on affected populations. Patients with
severe and highly penetrant dominant disorders are not represented
in general population studies, making it nearly impossible to find
data anywhere except a disease-focused cohort like Invitae's," said
Sun-Gou Ji, Ph.D., vice president of
computational genetics at BridgeBio. "These rich data sources will
continue to offer researchers a mechanism to get a much deeper
understanding of genetic variations and their effect on
diseases."
Together Invitae and BridgeBio will translate genetic and
phenotypic data into insights to improve therapeutic discovery and
design for patients with rare disease. Invitae will analyze
longitudinal medical phenotypes in linked genetic and clinical
datasets, in order to understand the burden of disease in a
real-world setting. Harnessing BridgeBio's disease expertise,
Invitae will leverage AI-based phenotypic clustering to identify
subgroups of patients based on their genetic and phenotypic
profiles. Invitae will also conduct association testing to identify
potential genetic modifiers of disease phenotype, severity, onset
and progression.
For more information about Invitae's solutions for biopharma
partners, visit
https://www.invitae.com/en/partners/biopharma.
About Invitae
Invitae (NYSE: NVTA) is a leading
medical genetics company trusted by millions of patients and their
providers to deliver timely genetic information using digital
technology. We aim to provide accurate and actionable answers to
strengthen medical decision-making for individuals and their
families. Invitae's genetics experts apply a rigorous approach to
data and research, serving as the foundation of their mission to
bring comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram, Facebook and LinkedIn @Invitae.
About BridgeBio
BridgeBio is a biotechnology company
on a mission to discover and deliver transformative medicines for
patients with genetic diseases and cancers with clear genetic
drivers.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the company's goals with respect to the
partnership; the intended structure and potential benefits of the
partnership; the company's beliefs regarding its dataset and
analytical capabilities; and the company's belief that the
partnership may support the development of novel therapeutic
targets and advance transformative medicines for patients with rare
disease. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties include, but are
not limited to: the company's ability to grow its business in a
cost-efficient manner; the company's history of losses; the
company's ability to maintain important customer relationships; the
company's ability to compete; the company's need to scale its
infrastructure in advance of demand for its tests and to increase
demand for its tests; the risk that the company may not obtain or
maintain sufficient levels of reimbursement for its tests; the
applicability of clinical results to actual outcomes; risks
associated with litigation; the company's ability to use rapidly
changing genetic data to interpret test results accurately and
consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2023.
These forward-looking statements speak only as of the date hereof,
and Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Invitae PR contact:
Renee Kelley
pr@invitae.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-partners-with--bridgebio-pharma-to-harness-genetic-insights-for-the-discovery-of-rare-disease-therapeutics-302047102.html
SOURCE Invitae Corporation